title: The incidence of pleural and pericardial effusion is not higher in patients receiving dasatinib at low doses. (Reply).
authors: Giuseppe
authors: G
authors: Visani
authors: Massimo
authors: M
authors: Breccia
authors: Enrico
authors: E
authors: Montefusco
authors: Enrica
authors: E
authors: Morra
authors: Valeria
authors: V
authors: Santini
authors: Alessandro
authors: A
authors: Isidori
mesh_terms: D000069439:Dasatinib; D006801:Humans; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D010490:Pericardial Effusion / Q000453:epidemiology* / Q000209:etiology*; D010996:Pleural Effusion / Q000453:epidemiology* / Q000209:etiology*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D000069439:Dasatinib